The First AI-Developed Drug is Set to Proceed to Clinical Trial

Getting your Trinity Audio player ready...

New drugs cost billions to develop on average, and take many years to reach the market – often over a decade. Artificial intelligence is changing the way pharmaceutical companies discover and develop new drugs, thanks to its ability to analyse very large datasets. AI is beginning to be used in drug target identification, patient recruitment, and post-market monitoring of safety.

http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf

DSP-1181, a serotonin receptor agonist and candidate for the treatment of obsessive-compulsive disorder, has been given the green light for phase 1 clinical trials. Developed using AI, the drug was made ready for trial less 12 months after its discovery – a remarkable rate of progress, considering this process takes an average of 6 or 7 years.

As companies continue to incorporate AI into drug development, we can hope to see significant reductions in both the cost and the time it takes for novel medications to reach the market.

We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery.
Andrew Hopkins, CEO of Exscientia
https://www.outsourcing-pharma.com/Article/2020/01/30/AI-developed-drug-goes-to-trial?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright